Finally, immunotherapies targeting the PD-1/PD-L1 pathway may represent novel therapeutic promises for advanced, recurrent and/or metastatic thyroid carcinomas, primarily in combination with BRAFi (Figure 2). This evidence concerns the gene PDCD1 and thyroid gland carcinoma.